Project title: NHS National Framework for Transition Products (Apremilast, Pazopanib and Dapagliflozin) commencing 1st February 2026
Offer reference number: CM/TNS/25/5735
Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to a maximum of 24 months.
Potential periods of call-offs under the framework agreement:
CM/TNS/25/5735 Apremilast, Pazopanib and Dapagliflozin
Lot 1 DLN/DNW: 01/02/2026 to 31/01/2027 (12 months)
Lot 2 DLS/DNE: 01/02/2026 to 31/01/2027 (12 months)
Lot 3 DCE/DSW: 01/02/2026 to 30/09/2027 (20 months)
Published By: Medicines Procurement and Supply Chain – NHS Medicines Value & Access, NHS England